secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001104659-26-046804
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec announces four PEDMARK abstracts accepted at 2026 ASCO meeting
---------------------------------------------------------------------

- Four abstracts evaluating PEDMARK accepted for presentation/publication at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago).
- Key poster: STS-J01 study on delayed sodium thiosulfate for cisplatin-induced ototoxicity in pediatric/adolescent patients.
- Other posters: randomized phase 1 trial in men with metastatic germ cell tumor; real-world feasibility in young adults; audiometric outcomes in head and neck cancer.
- Full abstracts will be available on ASCO website May 21, 2026 at 5:00 p.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926046804/0001104659-26-046804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926046804/fencf-20260422x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-046804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer